Article
Local tumour control and enucleation rate after 106Ru-Brachytherapy for Uveal Melanoma
Search Medline for
Authors
Published: | September 21, 2010 |
---|
Outline
Text
Purpose: To analyse local tumour control, radiation related complications and enucleation rate after 106Ru-brachytherapy of uveal melanoma.
Methods: A retrospective study was performed. 948 eyes with choroidal or ciliary body melanomas were treated with 106Ruthenium episcleral plaques from October 1992 through December 2005. The Kaplan-Meier method and Cox-Regression model were used for statistical analysis.
Results: The mean follow-up was 4.1 years (0.09-14.1 years). The mean tumour size was 5.1 mm ± 2.1 mm (min: 1.0 mm; max: 12.3 mm) at the time of treatment. The mean tumour base was 11.7 mm ±3.0 mm (min 2.7 mm, max 23.4 mm). 17.7% of eyes showed evidence of ciliary body infiltration and 3.9% had infiltration of the iris. 3.5% of eyes had extraocular growth. The local tumour control rates were 91.3% and 89.7% at 5 and 10 years, respectively. The mean time of appearance of tumour recurrences was 2 years ± 1.6 year (min 4 months; max 7.9 years.). The eye-preservation was 95.0% and 93.7% at 5 and 10 years, respectively. The reason for secondary enucleation was tumour recurrence in 66.7% and radiation-related complications in 33.3%.
Conclusions: 106Ru-Brachytherapy in the treatment of uveal melanoma is an effective method with a favourable local tumour control and eye preservation rate. The Life-long monitoring for recurrences is warranted.